Szerző:
Alison Laws, MD1
Ana C. Garrido-Castro, MD2
Philip D. Poorvu, MD3
Eric P. Winer, MD4
Elizabeth A. Mittendorf, MD, PhD5
Tari A. King, MD6
1Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA
2Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA
6Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, Harvard Medical School, Boston, MA
A 21 gén alapú rekurrens mutató (21-gene recurrence score, a továbbiakban RS) használatát sikeresen validálták prognosztikai és prediktív eszközként nyirokcsomó-negatív (pN0), ösztrogénreceptor-pozitív (ER+) és HER2-receptor-negatív (HER2−) emlőrákokban. Számottevő bizonyíték támasztja alá klinikai hasznosságát a nyirokcsomó-pozitív (pN+) betegekben is. Klinikai vizsgálatokban archivált szövettani minták ...